MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
BioNano Genomics Cost of Revenue 2011-2026 | BNGO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.3 M | 30.4 M | 26.6 M | 21.9 M | 14.1 M | 5.73 M | 6.77 M | 8.71 M | 6.03 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.4 M | 5.73 M | 15.1 M |
Quarterly Cost of Revenue BioNano Genomics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 M | 3.26 M | 3.52 M | - | 14.5 M | 5.19 M | 5.94 M | - | 6.57 M | 6.35 M | 5.34 M | - | 5.41 M | 5.2 M | 4.84 M | - | 3.5 M | 2.42 M | 2.12 M | - | 1.46 M | 603 K | 856 K | 1.69 M | 2.38 M | 1.56 M | 1.15 M | 2.99 M | 3.07 M | 1.81 M | 841 K | 1.5 M | 1.69 M | 1.64 M | 1.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.5 M | 603 K | 3.42 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 17.1 | 0.56 % | $ 181 M |  China |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 21.5 | 3.32 % | $ 1.15 B |  USA |
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 114.52 | -0.86 % | $ 34.8 B | USA |
 |
Co-Diagnostics
CODX
|
222 K | $ 1.55 | - | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 24.81 | 1.31 % | $ 689 M | USA |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
3.3 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 14.13 | -6.98 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 112.85 | -4.63 % | $ 9.31 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 135.78 | 7.13 % | $ 21.6 B | USA |
 |
Lantheus Holdings
LNTH
|
600 M | $ 85.5 | 1.04 % | $ 5.77 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
248 M | $ 4.8 | 1.05 % | $ 444 M | USA |
 |
NeoGenomics
NEO
|
413 M | $ 9.44 | 1.94 % | $ 1.21 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 26.16 | -0.87 % | $ 20 B |  Niderland |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
984 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
349 M | $ 87.6 | 0.6 % | $ 11 B | USA |
 |
Personalis
PSNL
|
57.8 M | $ 5.78 | 4.71 % | $ 342 M | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K |  Israel |
 |
Interpace Biosciences
IDXG
|
14.6 M | $ 2.12 | 7.07 % | $ 9.38 M | USA |
 |
Senseonics Holdings
SENS
|
19.5 M | $ 5.1 | -22.84 % | $ 213 M | USA |
 |
Soleno Therapeutics
SLNO
|
2.7 M | $ 52.87 | 0.09 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 60.4 | 3.34 % | $ 3.61 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.94 B | $ 255.84 | -0.37 % | $ 21.3 B | USA |
 |
Natera
NTRA
|
158 M | $ 207.28 | 0.54 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.53 | 1.38 % | $ 2.07 B | USA |
 |
Invitae Corporation
NVTA
|
92.8 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
363 M | $ 307.12 | -0.68 % | $ 18.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.37 B | $ 192.67 | -0.79 % | $ 21.4 B | USA |